Cargando…

lncRNA PVT1 identified as an independent biomarker for prognosis surveillance of solid tumors based on transcriptome data and meta-analysis

PURPOSE: Long noncoding RNA PVT1 is dysregulated in some human tumors and has been found to increase the risk of tumor progression and poor prognosis. This study aimed to reanalyze the effect of PVT1 on tumorous prognosis. MATERIALS AND METHODS: The effect of PVT1 on metastasis and survival were ana...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Xiaoliang, Yang, Yueying, Cao, Yong, Wu, Changjun, Wu, Shuxian, Su, Zhan, Jin, Hongwei, Wang, Dongli, Zhang, Gengxin, Fan, Wei, Lin, Jinbo, Zeng, Yunhong, Hu, Dongsheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101015/
https://www.ncbi.nlm.nih.gov/pubmed/30147369
http://dx.doi.org/10.2147/CMAR.S166260
_version_ 1783348976111583232
author Chen, Xiaoliang
Yang, Yueying
Cao, Yong
Wu, Changjun
Wu, Shuxian
Su, Zhan
Jin, Hongwei
Wang, Dongli
Zhang, Gengxin
Fan, Wei
Lin, Jinbo
Zeng, Yunhong
Hu, Dongsheng
author_facet Chen, Xiaoliang
Yang, Yueying
Cao, Yong
Wu, Changjun
Wu, Shuxian
Su, Zhan
Jin, Hongwei
Wang, Dongli
Zhang, Gengxin
Fan, Wei
Lin, Jinbo
Zeng, Yunhong
Hu, Dongsheng
author_sort Chen, Xiaoliang
collection PubMed
description PURPOSE: Long noncoding RNA PVT1 is dysregulated in some human tumors and has been found to increase the risk of tumor progression and poor prognosis. This study aimed to reanalyze the effect of PVT1 on tumorous prognosis. MATERIALS AND METHODS: The effect of PVT1 on metastasis and survival were analyzed by univariate logistic regression and Cox proportional hazards model for 32 types of cancer in the Cancer Genome Atlas database (TCGA), and the relationship between PVT1 level and expression of relative genes was assessed by Pearson correlation analysis. RevMan5.3 and STATA14.0 were used to estimate pooled effects of PVT1 on cancer prognosis with data from TCGA and published studies. RESULTS: In TCGA data, high PVT1 expression tended to increase the risk of TNM progression and decreased the overall survival (OS) time in most of cancers. The pooled effect of PVT1 on TNM (pooled-OR=1.46, 95% CI: 1.29–1.65) and OS (pooled HR=1.32, 95% CI: 1.22–1.43), calculated from 37 and 48 cohorts, identified that high PVT1 expression promoted the metastasis and poor prognosis of cancer. Furthermore, the pooled ORs of 2.77 (95% CI: 1.65–4.66), 4.32 (95% CI: 1.99–9.36), 1.35 (95% CI: 1.01–1.80), 1.62 (95% CI: 1.21–2.18) and 1.48 (95% CI: 1.02–2.15) provided evidence that PVT1 played a role in lymph node metastasis, depth of invasion, distant metastasis, differentiation and lymphatic invasion; while the expression of 24 identified target genes was significantly associated with PVT1 level, and high PVT1 expression dependently decreased the OS time under the influence of co-expression genes (OR=1.29, 95% CI: 1.25–1.32) in high-throughput RNA sequencing merging data. In addition, the expression of PVT1 could be upregulated by smoking, with the pooled OR being 1.09 (95% CI 1.01–1.16). CONCLUSION: PVT1 is a dependent biomarker for tumorous prognosis surveillance. However, the reference value of PVT1 needs further study.
format Online
Article
Text
id pubmed-6101015
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-61010152018-08-24 lncRNA PVT1 identified as an independent biomarker for prognosis surveillance of solid tumors based on transcriptome data and meta-analysis Chen, Xiaoliang Yang, Yueying Cao, Yong Wu, Changjun Wu, Shuxian Su, Zhan Jin, Hongwei Wang, Dongli Zhang, Gengxin Fan, Wei Lin, Jinbo Zeng, Yunhong Hu, Dongsheng Cancer Manag Res Review PURPOSE: Long noncoding RNA PVT1 is dysregulated in some human tumors and has been found to increase the risk of tumor progression and poor prognosis. This study aimed to reanalyze the effect of PVT1 on tumorous prognosis. MATERIALS AND METHODS: The effect of PVT1 on metastasis and survival were analyzed by univariate logistic regression and Cox proportional hazards model for 32 types of cancer in the Cancer Genome Atlas database (TCGA), and the relationship between PVT1 level and expression of relative genes was assessed by Pearson correlation analysis. RevMan5.3 and STATA14.0 were used to estimate pooled effects of PVT1 on cancer prognosis with data from TCGA and published studies. RESULTS: In TCGA data, high PVT1 expression tended to increase the risk of TNM progression and decreased the overall survival (OS) time in most of cancers. The pooled effect of PVT1 on TNM (pooled-OR=1.46, 95% CI: 1.29–1.65) and OS (pooled HR=1.32, 95% CI: 1.22–1.43), calculated from 37 and 48 cohorts, identified that high PVT1 expression promoted the metastasis and poor prognosis of cancer. Furthermore, the pooled ORs of 2.77 (95% CI: 1.65–4.66), 4.32 (95% CI: 1.99–9.36), 1.35 (95% CI: 1.01–1.80), 1.62 (95% CI: 1.21–2.18) and 1.48 (95% CI: 1.02–2.15) provided evidence that PVT1 played a role in lymph node metastasis, depth of invasion, distant metastasis, differentiation and lymphatic invasion; while the expression of 24 identified target genes was significantly associated with PVT1 level, and high PVT1 expression dependently decreased the OS time under the influence of co-expression genes (OR=1.29, 95% CI: 1.25–1.32) in high-throughput RNA sequencing merging data. In addition, the expression of PVT1 could be upregulated by smoking, with the pooled OR being 1.09 (95% CI 1.01–1.16). CONCLUSION: PVT1 is a dependent biomarker for tumorous prognosis surveillance. However, the reference value of PVT1 needs further study. Dove Medical Press 2018-08-16 /pmc/articles/PMC6101015/ /pubmed/30147369 http://dx.doi.org/10.2147/CMAR.S166260 Text en © 2018 Chen et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Review
Chen, Xiaoliang
Yang, Yueying
Cao, Yong
Wu, Changjun
Wu, Shuxian
Su, Zhan
Jin, Hongwei
Wang, Dongli
Zhang, Gengxin
Fan, Wei
Lin, Jinbo
Zeng, Yunhong
Hu, Dongsheng
lncRNA PVT1 identified as an independent biomarker for prognosis surveillance of solid tumors based on transcriptome data and meta-analysis
title lncRNA PVT1 identified as an independent biomarker for prognosis surveillance of solid tumors based on transcriptome data and meta-analysis
title_full lncRNA PVT1 identified as an independent biomarker for prognosis surveillance of solid tumors based on transcriptome data and meta-analysis
title_fullStr lncRNA PVT1 identified as an independent biomarker for prognosis surveillance of solid tumors based on transcriptome data and meta-analysis
title_full_unstemmed lncRNA PVT1 identified as an independent biomarker for prognosis surveillance of solid tumors based on transcriptome data and meta-analysis
title_short lncRNA PVT1 identified as an independent biomarker for prognosis surveillance of solid tumors based on transcriptome data and meta-analysis
title_sort lncrna pvt1 identified as an independent biomarker for prognosis surveillance of solid tumors based on transcriptome data and meta-analysis
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6101015/
https://www.ncbi.nlm.nih.gov/pubmed/30147369
http://dx.doi.org/10.2147/CMAR.S166260
work_keys_str_mv AT chenxiaoliang lncrnapvt1identifiedasanindependentbiomarkerforprognosissurveillanceofsolidtumorsbasedontranscriptomedataandmetaanalysis
AT yangyueying lncrnapvt1identifiedasanindependentbiomarkerforprognosissurveillanceofsolidtumorsbasedontranscriptomedataandmetaanalysis
AT caoyong lncrnapvt1identifiedasanindependentbiomarkerforprognosissurveillanceofsolidtumorsbasedontranscriptomedataandmetaanalysis
AT wuchangjun lncrnapvt1identifiedasanindependentbiomarkerforprognosissurveillanceofsolidtumorsbasedontranscriptomedataandmetaanalysis
AT wushuxian lncrnapvt1identifiedasanindependentbiomarkerforprognosissurveillanceofsolidtumorsbasedontranscriptomedataandmetaanalysis
AT suzhan lncrnapvt1identifiedasanindependentbiomarkerforprognosissurveillanceofsolidtumorsbasedontranscriptomedataandmetaanalysis
AT jinhongwei lncrnapvt1identifiedasanindependentbiomarkerforprognosissurveillanceofsolidtumorsbasedontranscriptomedataandmetaanalysis
AT wangdongli lncrnapvt1identifiedasanindependentbiomarkerforprognosissurveillanceofsolidtumorsbasedontranscriptomedataandmetaanalysis
AT zhanggengxin lncrnapvt1identifiedasanindependentbiomarkerforprognosissurveillanceofsolidtumorsbasedontranscriptomedataandmetaanalysis
AT fanwei lncrnapvt1identifiedasanindependentbiomarkerforprognosissurveillanceofsolidtumorsbasedontranscriptomedataandmetaanalysis
AT linjinbo lncrnapvt1identifiedasanindependentbiomarkerforprognosissurveillanceofsolidtumorsbasedontranscriptomedataandmetaanalysis
AT zengyunhong lncrnapvt1identifiedasanindependentbiomarkerforprognosissurveillanceofsolidtumorsbasedontranscriptomedataandmetaanalysis
AT hudongsheng lncrnapvt1identifiedasanindependentbiomarkerforprognosissurveillanceofsolidtumorsbasedontranscriptomedataandmetaanalysis